Circ_0004913 sponges miR-1290 and regulates FOXC1 to inhibit the proliferation of hepatocellular carcinoma
- PDF / 4,770,450 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 90 Downloads / 178 Views
Cancer Cell International Open Access
PRIMARY RESEARCH
Circ_0004913 sponges miR-1290 and regulates FOXC1 to inhibit the proliferation of hepatocellular carcinoma Yabin Yu1, Suyang Han2, Meng Li3, Yan Song1 and Fuzhen Qi1*
Abstract Background: Circular RNA (circRNA), an novel type of non-coding RNA, could interact with miRNA and protein molecules to regulate the occurrence and progression of hepatocellular carcinoma (HCC). However, little is known about the pathogenesis of circ_0004913 in HCC. Materials: Through the GEO (Gene Expression Omnibus database) to find dysfunctional circRNAs in HCC, and circ_0004913 was selected as the research object. Quantitative reverse transcription PCR (qRT-PCR) was used to detect the expression level of circ_0067934 in HCC tissues and cells. CCK-8, Edu and flow cytometry assays were used to determine the malignant behavior of transfected HCC cells. Mechanistically, RNA immunoprecipitation and dualluciferase reporter gene assay were performed to explore the relation between circ_0067934, miR-1290 and FOXC1 (Forkhead box C1) in HCC. Results: The expression of circ_0004913 was down-regulated in HCC tissues and cell lines, while the overexpression of circ_0004913 attenuates the malignant behavior of HCC cells. Bioinformatics predicted that circ_0004913 interacts with miR-1290, which targeted FOXC1 mRNA. In fact, miR-1290 promoted the malignant behavior of HCC cells, while FOXC1 had the opposite effect. In addition, circ_0004913 overexpression enhanced FOXC1 expression by reducing miR-1290 expression, thereby inhibiting the proliferation of HCC cells. Conclusions: Circ_0004913 / miR-1290 / FOXC1 regulatory axis could inhibit the progress of HCC. Our findings may provide potential new targets for the diagnosis and treatment of HCC. Keywords: Circ_0004913, miR-1290, FOXC1, Proliferation, Hepatocellular carcinoma Introduction Accounting for approximately 90% of primary liver cancer, Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths in the world [1, 2]. Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), heavy alcohol consumption and diabetes are the main risk factors for HCC [3]. There are currently several treatments *Correspondence: [email protected] 1 Department of Hepatobiliary Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, 1 West Huanghe Road, Huai’an 223300, Jiangsu, People’s Republic of China Full list of author information is available at the end of the article
for HCC, including surgical resection, chemoradiation, and liver transplantation. Sometimes, hepatocellular carcinoma requires a multidisciplinary treatment to get the best results [4]. However, the 5-year overall survival rates of patients with HCC remain low, largely because of metastasis and recurrence [5]. In order to improve the diagnosis and prognosis of HCC patients, it is particularly critical to discover and identify new targets for precise treatment. Circular RNAs (circRNAs) are a new type of non-coding RNAs, characterized by con
Data Loading...
